GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (OTCPK:RVXCF) » Definitions » Ending Cash Position

RVXCF (Resverlogix) Ending Cash Position : $0.10 Mil (As of Dec. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Resverlogix Ending Cash Position?

Resverlogix's Ending Cash Position for the quarter that ended in Dec. 2024 was $0.10 Mil.

Resverlogix's quarterly Ending Cash Position declined from Jun. 2024 ($0.06 Mil) to Sep. 2024 ($0.04 Mil) but then increased from Sep. 2024 ($0.04 Mil) to Dec. 2024 ($0.10 Mil).

Resverlogix's annual Ending Cash Position declined from Dec. 2022 ($0.04 Mil) to Dec. 2023 ($0.01 Mil) but then increased from Dec. 2023 ($0.01 Mil) to Dec. 2024 ($0.10 Mil).


Resverlogix Ending Cash Position Historical Data

The historical data trend for Resverlogix's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resverlogix Ending Cash Position Chart

Resverlogix Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23 Dec24
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.01 0.04 0.01 0.10

Resverlogix Quarterly Data
Jan20 Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.06 0.06 0.04 0.10

Resverlogix Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Resverlogix's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.0049999999999999+0.094
=0.10

Resverlogix's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.041+0.058
=0.10


Resverlogix Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Resverlogix's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


Resverlogix Business Description

Traded in Other Exchanges
Address
4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.

Resverlogix Headlines